

161. Glicksman RM, Metser U, Vines D et al: Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: A prospective phase ii trial testing the oligometastasis hypothesis. *Eur Urol* 2021; **80**: 374
162. Glicksman RM, Ramotar M, Metser U et al: Extended results and independent validation of a phase 2 trial of metastasis-directed therapy for molecularly defined oligometastatic prostate cancer. *Int J Radiat Oncol Biol Phys* 2022; **114**: 693
163. Hussain M, Carducci MA, Clarke N et al: Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: More questions than answers? *J Clin Oncol* 2022; **40**: 3011
164. Freedland SJ, de Almeida Luz M, De Giorgi U et al: Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. *N Engl J Med* 2023; **389**: 1453